Vocinti Vonoprazan Fumarate Tablets

1. Indications and Usage
Treatment of Reflux Esophagitis (RE): Treatment of adult patients with reflux esophagitis .
Helicobacter pylori Eradication: Treatment of Helicobacter pylori-infected patients in combination with appropriate antibiotics (e.g., amoxicillin, clarithromycin) .
2. Dosage and Administration
Administration: Oral administration. Can be taken with or without food .
Reflux Esophagitis:
Recommended Dose: 20 mg once daily.
Duration: Most patients benefit within 4 weeks. If efficacy is insufficient, the course may be extended to a maximum of 8 weeks .
Maintenance: For maintenance therapy of recurrent RE, 10 mg once daily (may increase to 20 mg if ineffective) .
H. pylori Eradication: 20 mg twice daily for 14 days, in combination with amoxicillin (1000 mg twice daily) and clarithromycin (200-250 mg twice daily) .
Missed Dose: If a dose is missed, take it as soon as possible on the same day. Resume the normal schedule the next day. Do not take a double dose .
3. Mechanism of Action
Vonoprazan is a Potassium-Competitive Acid Blocker (P-CAB).
Unlike Proton Pump Inhibitors (PPIs) which require activation in acidic environments and form irreversible bonds, Vonoprazan blocks the H+/K+-ATPase enzyme by competing with potassium ions at the binding site. This allows for rapid, reversible, and strong acid suppression immediately upon administration .
4. Safety and Warnings
Embryo-Fetal Toxicity: May cause fetal harm. Use is not recommended during pregnancy or breastfeeding unless the benefit outweighs the risk .
Hepatotoxicity: Liver function abnormalities have been reported. Monitor liver enzymes periodically .
Masking of Gastric Cancer: Treatment may mask symptoms of gastric malignancy. Malignancy should be ruled out before initiating therapy for dyspepsia .
Risk of Infections: Increased gastric pH increases susceptibility to infections, including Clostridioides difficile .
Bone Fracture Risk: Long-term or high-dose use (≥1 year) has been associated with an increased risk of osteoporosis-related fractures (hip, wrist, spine) .
5. Adverse Reactions
Common adverse reactions (incidence ≥1% or frequent in trials) include:
Gastrointestinal: Diarrhea, Constipation, Nausea, Abdominal distension .
Hepatic: Elevated liver enzymes (ALT, AST, GGT, ALP) .
Dermatologic: Rash, Pruritus .
Neurologic: Headache .
6. Drug Interactions
Contraindicated: Atazanavir and Rilpivirine (absorption is pH-dependent and significantly reduced) .
CYP3A4 Substrates: Vonoprazan is metabolized by CYP3A4. Co-administration with strong inhibitors (e.g., Clarithromycin) increases Vonoprazan exposure .
pH-Dependent Drugs: May alter absorption of drugs requiring acidic pH (e.g., Itraconazole, Erlotinib, Gefitinib) .
Digoxin: Vonoprazan may increase digoxin exposure; monitor levels .
7. Pharmaceutical Information
Chemical Name: 1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine monofumarate .
Molecular Formula: C17H16FN3O2S · C4H4O4 .
Storage: Store at or below 30°C in a dry place, protected from light .